GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptinyx Inc (OTCPK:APTX) » Definitions » Net Cash per Share

Aptinyx (Aptinyx) Net Cash per Share : $0.22 (As of Mar. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Aptinyx Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Aptinyx's Net Cash per Share for the quarter that ended in Mar. 2023 was $0.22.

The historical rank and industry rank for Aptinyx's Net Cash per Share or its related term are showing as below:

APTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.44   Med: 1.46   Max: 6.11
Current: 0.44

During the past 7 years, the highest Price-to-Net-Cash Ratio of Aptinyx was 6.11. The lowest was 0.44. And the median was 1.46.

APTX's Price-to-Net-Cash is not ranked
in the Biotechnology industry.
Industry Median: 4.14 vs APTX: 0.44

Aptinyx Net Cash per Share Historical Data

The historical data trend for Aptinyx's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptinyx Net Cash per Share Chart

Aptinyx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Cash per Share
Get a 7-Day Free Trial 4.33 2.78 2.16 1.27 0.41

Aptinyx Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 0.81 0.58 0.41 0.22

Competitive Comparison of Aptinyx's Net Cash per Share

For the Biotechnology subindustry, Aptinyx's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptinyx's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptinyx's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Aptinyx's Price-to-Net-Cash falls into.



Aptinyx Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Aptinyx's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(56.205-28.399-0)/67.716
=0.41

Aptinyx's Net Cash per Share for the quarter that ended in Mar. 2023 is calculated as

Net Cash per Share (Q: Mar. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(44.573-29.707-0)/67.716
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptinyx  (OTCPK:APTX) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Aptinyx Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Aptinyx's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptinyx (Aptinyx) Business Description

Traded in Other Exchanges
N/A
Address
909 Davis Street, Suite 600, Evanston, IL, USA, 60201
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.
Executives
Joan W. Miller director C/O APTINYX INC., 909 DAVIS ST., SUITE 600, EVANSTON IL 60201
Norbert G Riedel director, officer: CEO and President BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Ashish Khanna officer: CFO and CBO 909 DAVIS STREET, SUITE 600, EVANSTON IL 60201
Robert J. Hombach director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Gilmore Neil O'neill director 215 FIRST STREET, CAMBRIDGE MA 02142
Bain Capital Life Sciences Investors, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Rachel E. Sherman director 909 DAVIS STREET, SUITE 600, EVANSTON IL 60201
Bain Capital Life Sciences Fund, L.p. 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Life Sciences Partners, Lp 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Jeffrey Lawrence Schwartz 10 percent owner C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116
Bcip Life Sciences Associates, Lp 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Adam Koppel director C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Henry O Gosebruch director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Patrick G Enright director, 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025

Aptinyx (Aptinyx) Headlines

From GuruFocus

Aptinyx to Participate in the 42nd Annual Cowen Health Care Conference

By Business Wire Business Wire 03-01-2022

Aptinyx to Participate in H.C. Wainwright Global Investment Conference

By Business Wire Business Wire 05-18-2022